What is the difference between spaxentan/sparsentan and atrasentan?

Sparsentan and atrasentan are two drugs used to treat kidney diseases, especially in the management of immunoglobulin A nephropathy (IgAN) and other chronic kidney diseases. Although they all belong to the same drug class, there are significant differences in mechanisms, clinical trial results, side effects, and market positioning.

Mechanistically, sparsentane acts as a dual receptor antagonist, targeting endothelinA receptor (ETAR) and angiotensin II subtype 1 receptor (AT1R). Therefore, sparsentane can protect renal function by reducing proteinuria and reducing renal inflammation by inhibiting these two pathways. Relatively speaking, atrasentan mainly acts as an endothelin A receptor antagonist. Although it also has certain anti-inflammatory and diuretic effects, its mechanism of action is relatively simple.

In terms of clinical trial results, spaxentan received accelerated approval for IgAN from the U.S. Food and Drug Administration (FDA) on February 17, 2023. However, this approval was accompanied by some limitations, such as higher-than-expected proteinuria (UPCR ≥1.5g/g) and cumbersome REMS monitoring requirements, which affected the flexibility of its clinical application. Relatively speaking, atrasentan showed a stronger improvement in proteinuria in the phase 2 clinical trial. The data showed that proteinuria was reduced by approximately 54.7% at week 24, which means that atrasentan may perform better than spaxentan in phase 3.

In terms of side effects, sparsentane is associated with some gastrointestinal side effects, such as diarrhea, which has a certain impact on patient tolerance. In contrast, atrasentan has shown good tolerability and safety in clinical studies, which may make it more convenient in patient management. Atrasentan's lower potency is also thought to translate into a more predictable and manageable safety profile, giving physicians more options when prescribing the drug.

In terms of market positioning, due to sparsentan'sFDA approval and subsequent restrictions, some people think that its market positioning is not as clear as atrasentan. However, atrasentan offers prescribers more flexibility as a drug that can be mixed and matched with RASi (such as ACEi and ARB). When patients develop conditions such as hypotension, doctors can adjust the dose of ACEi accordingly, which is not possible with sparsentan. In addition, atrasentan is suitable for patients whose UPCR is lower than the standard specified by the FDA label (≥1.5g/g), which makes atrasentan a potential advantage in early clinical intervention.

Although sparsentan and atrasentan compete in some aspects, their differences make them complementary in clinical applications. Doctors can choose the most appropriate treatment plan based on the patient's specific situation and needs to achieve the best treatment effect. With further research and data accumulation, the understanding of these two drugs will continue to deepen, and more guidance can be provided for clinical practice.

Reference materials:https://seekingalpha.com/article/4580494-chinook-travere-sparsentan-approval-net-positive